{"database":"GEO","file_versions":[{"headers":{"Content-Type":["application/json"]},"body":{"files":{"Other":["ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE303nnn/GSE303810/"]},"type":"primary"},"statusCodeValue":200,"statusCode":"OK"}],"scores":null,"additional":{"omics_type":["Transcriptomics"],"species":["Homo sapiens"],"gds_type":["Expression profiling by high throughput sequencing"],"full_dataset_link":["https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE303810"],"repository":["GEO"],"entry_type":["GSE"],"additional_accession":[]},"is_claimable":false,"name":"snRNA-seq profiles distinguish anti-Drebrin- and anti-GAD65-positive encephalitis","description":"Autoantibodies (ABs) against intracellular proteins, including glutamate-decarboxylase 65 (anti-GAD65), are increasingly recognized in autoimmune and limbic encephalitis (AE/LE). Anti-GAD65 LE frequently progresses into severe temporal lobe epilepsy (TLE), neuropathologically characterized by hippocampal sclerosis (HS) and variable cytotoxic T lymphocytes (CTLs) infiltration. Recently, we have identified Drebrin as a novel intracellular target protein of ABs in patients suspicious for AE. Here, we report on the hippocampal neuropathological sequelae and single-nuclei RNA sequencing (snRNA-seq) of anti-Drebrin- versus anti-GAD65-positive TLE patients, in concert with key clinical parameters from a large patient cohort.","dates":{"publication":"2026/07/09"},"accession":"GSE303810","cross_references":{"GSM":["GSM9136272","GSM9136271","GSM9136274","GSM9136273","GSM9136276","GSM9136275","GSM9136277","GSM9136270"],"GPL":["24676"],"GSE":["303810"],"taxon":["Homo sapiens"],"PMID":["[42415095]"]}}